{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:39:11Z","timestamp":1780601951466,"version":"3.54.1"},"reference-count":44,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Introduction: Combination therapy with daptomycin plus ceftaroline to treat methicillin-resistant Staphylococcus aureus bacteremia has been reported to reduce methicillin-resistant Staphylococcus aureus bacteremia-related mortality. The purpose of the current meta-analysis was to compare the clinical outcome of methicillin-resistant Staphylococcus aureus bacteremia in patients treated with daptomycin or vancomycin plus ceftaroline combination therapy versus daptomycin or vancomycin monotherapy. Methods: Studies were included if they directly compared the efficacy of daptomycin or vancomycin plus ceftaroline combination therapy with that of daptomycin or vancomycin monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia in adult patients. Results: One randomized controlled trial and five retrospective studies were included in the meta-analysis. The combination therapy group had an in-hospital mortality, duration of bacteremia, and adverse event rate similar to those patients who had monotherapy. There was less bacteremia recurrence in the combination group. Initial combination therapy with ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia showed a trend of reducing the risk of in-hospital mortality in the current meta-analysis. Conclusions: Randomized controlled trials are needed to further study the role of initial combination therapy with daptomycin or vancomycin plus ceftaroline in the treatment of methicillin-resistant Staphylococcus aureus bacteremia.<\/jats:p>","DOI":"10.3390\/antibiotics11081104","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T20:58:08Z","timestamp":1660597088000},"page":"1104","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comparing the Outcomes of Ceftaroline plus Vancomycin or Daptomycin Combination Therapy versus Vancomycin or Daptomycin Monotherapy in Adults with Methicillin-Resistant Staphylococcus aureus Bacteremia\u2014A Meta-Analysis"],"prefix":"10.3390","volume":"11","author":[{"given":"Chienhsiu","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihung","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nursing, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"Jensen","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1086\/598189","article-title":"Staphylococcus aureus bacteremia: Epidemiology, pathophysiology, and management strategies","volume":"48","author":"Naber","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/archinte.167.17.1861","article-title":"Persistent Staphylococcus aureus bacteremia: An analysis of risk factors and outcomes","volume":"167","author":"Hawkins","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"E291","DOI":"10.1111\/1469-0691.12169","article-title":"Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: A retrospective cohort study in a region with low MRSA prevalence","volume":"19","author":"Forstner","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/jac\/dkq188","article-title":"Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan","volume":"65","author":"Lin","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/jac\/dkq050","article-title":"Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin","volume":"65","author":"Yoon","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.ijantimicag.2013.04.006","article-title":"Treatment of bacteraemia: Meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA)","volume":"42","author":"Gould","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10096-007-0455-5","article-title":"High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacte\u00acremia","volume":"27","author":"Sharma","year":"2008","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/jac\/dkr066","article-title":"Daptomycin non-susceptibility in vancomycin- intermediate Staphylococcus aureus (VISA) and heterogeneous- VISA (hVISA): Implications for therapy after vancomycin treatment failure","volume":"66","author":"Kelley","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jac\/dkt396","article-title":"Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin","volume":"69","author":"Gasch","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/cis563","article-title":"In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: A review of published studies and the AWARE Surveillance Program (2008\u20132010)","volume":"55","author":"Farrell","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"iii11","DOI":"10.1093\/jac\/dkr095","article-title":"Ceftaroline fosamil: A new broad-spectrum cephalosporin","volume":"66","author":"Laudano","year":"2011","journal-title":"J. Antimicrob Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/dkp503","article-title":"Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae","volume":"65","author":"Moisan","year":"2010","journal-title":"J. Antimicrob Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.mib.2007.08.003","article-title":"Antibiotic resistant Staphylococcus aureus: A paradigm of adaptive power","volume":"10","author":"Oliveira","year":"2007","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other \u03b2-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"McGhee","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1093\/cid\/cis559","article-title":"Summary of ceftaroline fosamil clinical trial studies and clinical safety","volume":"55","author":"File","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ofx084","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: A systematic review","volume":"4","author":"Cosimi","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"Zasowski","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.01586-12","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"ofab606","DOI":"10.1093\/ofid\/ofab606","article-title":"Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant Staphylococcus aureus bloodstream infection","volume":"9","author":"Zasowski","year":"2021","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: A pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.clinthera.2014.09.005","article-title":"Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia","volume":"36","author":"Dhand","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_27","first-page":"1","article-title":"Daptomycin plus beta-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: A retrospective, comparative cohort study","volume":"20","author":"Jorgensen","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/dku378","article-title":"The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA","volume":"70","author":"Barber","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/23744235.2018.1448110","article-title":"Daptomycin and combination daptomycin-ceftaroline as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"50","author":"Oliver","year":"2018","journal-title":"Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e02483-18","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments","volume":"7","author":"McCreary","year":"2019","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s10096-020-03941-5","article-title":"A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli","volume":"39","author":"Morrisette","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40121-019-00277-2","article-title":"Comparing the outcomes of ceftaroline plus vancomycin or daptomycin combination therapy versus monotherapy in adults with complicated and prolonged methicillin-resistant Staphylococcus aureus bacteremia initially treated with supplemental ceftaroline","volume":"9","author":"Ahmad","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"106310","DOI":"10.1016\/j.ijantimicag.2021.106310","article-title":"Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care","volume":"57","author":"Johnson","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Huang, C., Chen, I., and Yang, Y. (2022). Doripenem in the Treatment of Patients with Nosocomial Pneumonia: A Meta-Analysis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11144014"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jgar.2020.09.024","article-title":"Systematic review and meta-analysis of the efficacy and safety of vancomycin combined with \u03b2-lactam antibiotics in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"23","author":"Ye","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e01377-20","DOI":"10.1128\/AAC.01377-20","article-title":"Adjuvant \u03b2-lactam therapy combined with vancomycin or daptomycin for methicillin-resistant Staphylococcus aureus bacteremia: A systematic review and meta-analysis","volume":"64","author":"Wang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/phar.2437","article-title":"Combination of vancomycin or daptomycin and beta-lactam antibiotics: A meta-analysis","volume":"40","author":"Giuliano","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/mdr.2020.0350","article-title":"Vancomycin or daptomycin Plus a \u03b2-lactam versus vancomycin or daptomycin alone for methicillin-resistant Staphylococcus aureus bloodstream infections: A systematic review and meta-analysis","volume":"27","author":"Yi","year":"2021","journal-title":"Microb. Drug Resist."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: How much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/phar.2034","article-title":"Early administration of adjuvant blactam therapy in combination with vancomycin among patients with methicillin-resistant Staphylococcus aureus bloodstream infection: A retrospective, multicenter analysis","volume":"37","author":"Casapao","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","article-title":"Defining persistent Staphylococcus aureus bacteraemia: Secondary analysis of a prospective cohort study","volume":"20","author":"Kuehl","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciz257","article-title":"Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes","volume":"70","author":"Minejima","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/cid\/ciz112","article-title":"Changing characteristics of Staphylococcus aureus bacteremia: Results from a 21-Year, prospective, longitudinal study","volume":"69","author":"Souli","year":"2019","journal-title":"Clin. Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/8\/1104\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:08:47Z","timestamp":1760141327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/8\/1104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["antibiotics11081104"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11081104","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]}}}